



**ANTIMICROBIAL SUSCEPTIBILITY PROFILE (01/01/2022 to 12/31/2022)**  
**MedStar Southern Maryland Hospital Center**

 <b>MedStar Southern Maryland Hospital Center</b> Gram Negative Organisms	Percent Susceptible																			
	Number of Isolates	Amikacin****	Amoxicillin-Clavulanate	Ampicillin	Ampicillin/sulbactam	Aztreonam	Cefazolin (Systemic <sup>a</sup> )	Cefazolin (Urine <sup>b</sup> )	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	ESBL (Negative)	Gentamicin****	Levofloxacin	Meropenem	Nitrofurantoin*	Piperacillin/tazobactam	Tobramycin****	Trimethoprim/Sulfa
Acinetobacter baumannii	11**	28	-	-	28	-	-	16	-	10	-	-	-	-	-	-	-	21	-	
Enterobacter cloacae	47	100	0	0	-	67	-	79	70	64	70	-	96	-	94	0	72	94	89	
Escherichia coli	678	100	0	42	-	82	44	51	87	80	80	58	84	86	-	100	97	96	85	67
Klebsiella pneumoniae ssp pneumoniae	273	100	0	0	-	64	33	41	69	63	64	59	62	90	-	92	0	71	84	71
Proteus mirabilis	90	91	0	0	-	93	0	72	90	94	89	59	-	83	-	-	0	0	84	79
Pseudomonas aeruginosa	144	99	0	0	-	58	-	-	70	71	0	65	-	-	-	67	0	65	94	0
Stenotrophomonas maltophilia	26**	-	-	-	-	-	-	-	-	-	-	-	-	-	77	-	-	-	-	100

 <b>MedStar Southern Maryland Hospital Center</b> Gram Positive Organisms	Percent Susceptible															
	Number of Isolates	Ampicillin	Ceftriaxone (meningitis)	Ceftriaxone (non meningitis)	Clindamycin	Daptomycin	Erythromycin	Linezolid	Moxifloxacin	Nitrofurantoin*	Oxacillin	Penicillin (meningitis)	Penicillin (non-meningitis)	Tetracycline	Trimethoprim/Sulfa	Vancomycin
Enterococcus faecalis	103	100	-	-	0	99	-	100	-	100	-	-	-	14	0	100
Enterococcus faecium	7**	43	-	-	0	100	-	100	-	0	-	-	-	50	0	56
Methicillin resistant Staphylococcus aureus (MRSA)***	94	0	-	-	54	98	18	100	-	100	0	-	-	86	87	100
Methicillin sensitive Staphylococcus aureus (MSSA)	116	0	-	-	81	100	69	100	-	100	100	-	-	98	95	100
Staphylococcus coagulase-negative	183	0	-	-	70	100	-	100	-	0	48	-	-	0	70	100

Percent Susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient

(-) Drug not tested or drug not indicated

(\*) Tested on urine isolate only (\*\*) Data on the number of isolates less than 30 may not be statistically significant

(\*\*\*) MRSA rate of the institution was 44% (\*\*\*\*) Based on CLSI M100-32nd Ed breakpoints

<sup>a</sup> Cefazolin (systemic), MIC ≤ 2 µg/mL susceptible for infections other than uncomplicated UTIs

<sup>b</sup> Cefazolin (urine), MIC ≤ 16 µg/mL susceptible